Curis Inc - ESG Rating & Company Profile powered by AI
This webpage of Curis Inc is assembled by All Street Sevva using advanced Cognitive Robots. The assessment of Curis Inc incorporates information from across the web and also from available disclosures by Curis Inc. Complete Sustainability assessment of Curis Inc can be accessed by signing up for free.
Curis Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 6.4, social score of 3.2 and governance score of 4.0.
4.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1082 | Respiratorius AB (publ) | 4.9 | High |
| 1082 | Shenzhen Chipscreen Biosciences Co Ltd | 4.9 | High |
| 1121 | Curis Inc | 4.8 | High |
| 1121 | Heat Biologics Inc | 4.8 | High |
| 1121 | CureVac NV | 4.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Curis Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Curis Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Curis Inc report the average age of the workforce?
Sign up for free to unlockDoes Curis Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Curis Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Curis Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Curis Inc offer flexible work?
Sign up for free to unlockDoes Curis Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Curis Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Curis Inc conduct supply chain audits?
Sign up for free to unlockDoes Curis Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Curis Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Curis Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Curis Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Curis Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Curis Inc disclose water use targets?
Sign up for free to unlockDoes Curis Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Curis Inc have a product recall in the last two years?
Sign up for free to unlockDoes Curis Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Curis Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Curis Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Curis Inc disclose parental leave metrics?
Sign up for free to unlockDoes Curis Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Curis Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Curis Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Curis Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Curis Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Curis Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Curis Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Curis Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Curis Inc disclose its waste policy?
Sign up for free to unlockDoes Curis Inc report according to TCFD requirements?
Sign up for free to unlockDoes Curis Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Curis Inc disclose energy use targets?
Sign up for free to unlockDoes Curis Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Curis Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Curis Inc
These potential risks are based on the size, segment and geographies of the company.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.